User profiles for M. Neil Reaume
 | Martin Neil ReaumeVerified email at toh.on.ca Cited by 4164 |
[HTML][HTML] Enzalutamide with standard first-line therapy in metastatic prostate cancer
Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved
overall survival in men with castration-resistant prostate cancer. It is not known whether …
overall survival in men with castration-resistant prostate cancer. It is not known whether …
[HTML][HTML] Rucaparib or physician's choice in metastatic prostate cancer
K Fizazi, JM Piulats, MN Reaume… - … England Journal of …, 2023 - Mass Medical Soc
Background In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP),
showed a high level of activity in patients who had metastatic, castration-resistant …
showed a high level of activity in patients who had metastatic, castration-resistant …
[HTML][HTML] Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
…, M Zemanova, LA Wood, MN Reaume… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
… M. Neil Reaume … Suttle AB, Ball HA, Molimard M, et al.: Relationships between
pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell …
pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell …
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Background: Erythropoiesis-stimulating agents are used to treat anemia in patients with
cancer. However, their safety and effectiveness is controversial. We did a systematic review of …
cancer. However, their safety and effectiveness is controversial. We did a systematic review of …
Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival
Importance There exists considerable biological and clinical variability between histologic
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …
[HTML][HTML] Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG …
…, GB Rodrigues, L Souhami, MN Reaume… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard
treatment option for patients with high-risk localized prostate cancer. We hypothesized that …
treatment option for patients with high-risk localized prostate cancer. We hypothesized that …
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
…, E Winquist, C Elser, A Eisen, MN Reaume… - The lancet …, 2013 - thelancet.com
Background No standard treatment exists for patients with platinum-refractory urothelial
cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no …
cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no …
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for …
…, AG Balogh, G Rodrigues, L Souhami, MN Reaume… - 2015 - ascopubs.org
LBA5002 Background: High-risk, localized prostate cancer (PCa) patients have a relatively
poor prognosis. We hypothesized that the addition of adjuvant docetaxel and prednisone to …
poor prognosis. We hypothesized that the addition of adjuvant docetaxel and prednisone to …
Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 …
… M. Neil Reaume has received consulting fees/honoraria from Bayer, Pfizer, BristolMyers
Squibb, AstraZeneca, Novartis, Eisai, Ipsen, Merck, and Roche; and is a consultant for Astellas. …
Squibb, AstraZeneca, Novartis, Eisai, Ipsen, Merck, and Roche; and is a consultant for Astellas. …
Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy
Men who initially present with localized prostate cancer and later develop metachronous
metastases have a better prognosis than men with de novo metastatic disease and often have …
metastases have a better prognosis than men with de novo metastatic disease and often have …
